These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23618355)

  • 1. Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.
    de Castro CV; Guimaraes G; Aguiar S; Lopes A; Baiocchi G; da Cunha IW; Campos AH; Soares FA; Begnami MD
    Hum Pathol; 2013 Sep; 44(9):1747-55. PubMed ID: 23618355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
    Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
    J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor (EGFR) status in chordoma.
    Ptaszyński K; Szumera-Ciećkiewicz A; Owczarek J; Mrozkowiak A; Pekul M; Barańska J; Rutkowski P
    Pol J Pathol; 2009; 60(2):81-7. PubMed ID: 19886182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma.
    Fasig JH; Dupont WD; LaFleur BJ; Olson SJ; Cates JM
    Neuropathol Appl Neurobiol; 2008 Feb; 34(1):95-104. PubMed ID: 17973908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
    Weinberger PM; Yu Z; Kowalski D; Joe J; Manger P; Psyrri A; Sasaki CT
    Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):707-11. PubMed ID: 16103303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogene alterations in endometrial carcinosarcomas.
    Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
    Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: a series of 52 patients.
    Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
    Anticancer Res; 2014 Feb; 34(2):623-30. PubMed ID: 24510991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
    Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
    Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.
    Schirosi L; Lantuejoul S; Cavazza A; Murer B; Yves Brichon P; Migaldi M; Sartori G; Sgambato A; Rossi G
    Am J Surg Pathol; 2008 Nov; 32(11):1627-42. PubMed ID: 18753943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.
    Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H
    Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
    Tamborini E; Miselli F; Negri T; Lagonigro MS; Staurengo S; Dagrada GP; Stacchiotti S; Pastore E; Gronchi A; Perrone F; Carbone A; Pierotti MA; Casali PG; Pilotti S
    Clin Cancer Res; 2006 Dec; 12(23):6920-8. PubMed ID: 17145809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.
    Tamborini E; Virdis E; Negri T; Orsenigo M; Brich S; Conca E; Gronchi A; Stacchiotti S; Manenti G; Casali PG; Pierotti MA; Pilotti S
    Neuro Oncol; 2010 Aug; 12(8):776-89. PubMed ID: 20164240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein.
    Ostroumov E; Hunter CJ
    Spine (Phila Pa 1976); 2008 Dec; 33(25):2774-80. PubMed ID: 19050584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of receptor tyrosine kinases in esophageal carcinosarcoma.
    Sano A; Sakurai S; Kato H; Suzuki S; Yokobori T; Sakai M; Tanaka N; Inose T; Sohda M; Nakajima M; Fukai Y; Miyazaki T; Ojima H; Hosoya Y; Enomoto T; Kanda T; Ajioka Y; Kuwano H
    Oncol Rep; 2013 Jun; 29(6):2119-26. PubMed ID: 23546020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
    Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
    Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.
    Liang C; Ma Y; Yong L; Yang C; Wang P; Liu X; Zhu B; Zhou H; Liu X; Liu Z
    Cancer Sci; 2019 Jan; 110(1):166-179. PubMed ID: 30426615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study.
    Scheipl S; Froehlich EV; Leithner A; Beham A; Quehenberger F; Mokry M; Stammberger H; Varga PP; Lazáry A; Windhager R; Gattenloehner S; Liegl B
    Histopathology; 2012 May; 60(6):999-1003. PubMed ID: 22372631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression.
    Walter BA; Begnami M; Valera VA; Santi M; Rushing EJ; Quezado M
    J Neurooncol; 2011 Jan; 101(2):199-206. PubMed ID: 20617367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
    Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
    Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer.
    Kurokawa Y; Matsuura N; Kawabata R; Nishikawa K; Ebisui C; Yokoyama Y; Shaker MN; Hamakawa T; Takahashi T; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S584-90. PubMed ID: 24743909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.